GlassScriptPhysician profile
Ashley J Bennett
NPI 1912905985
$8,824.12
in general payments reported to CMS, 2019-2025
56 companies · $2,078 in 2025
The $2,078 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $709 · 2020: $471 · 2021: $931 · 2022: $1,326 · 2023: $1,495 · 2024: $1,814 · 2025: $2,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,386.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,125.39 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $775.75 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $672.62 | 2019-2025 | |
| Novo Nordisk INC | $659.32 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $574.37 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $473.50 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $462.23 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $423.46 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Glaxosmithkline, LLC. | $315.92 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.66 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $243.86 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $210.30 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $189.38 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $169.25 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.86 | 2025 | Caplyta |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.